This is not a big deal: Jefferies managing director on Eli Lilly pausing Covid-19 trials
Eli Lilly's phase three trial of its monoclonal antibody treatment for coronavirus has been paused due to potential safety concerns. This comes shortly after Johnson and Johnson and AstraZeneca also paused its Covid-19 clinical trials. Michael Yee, Jefferies managing director, joins 'Closing Bell' to say it's common to have clinical trials paused to investigate further information about the treatment. He joins to discuss.